Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by PMV Pharmaceuticals, Inc. on June 8, 2023. The meeting was conducted exclusively via live webcast.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three proposals with the following outcomes:
- Proposal 1: Election of Directors
- Richard Heyman, Ph.D.: Elected (28,709,696 For; 6,665,802 Withheld).
- David H. Mack, Ph.D.: Elected (35,181,696 For; 193,802 Withheld).
- Laurie Stelzer: Elected (34,128,780 For; 1,246,718 Withheld).
- All three directors were elected to serve until the 2026 Annual Meeting.
- Proposal 2: Executive Compensation (Say-on-Pay)
- Approved on a non-binding advisory basis (34,537,890 For; 836,543 Against).
- The Company will continue annual advisory votes on executive compensation until the 2028 annual meeting.
- Proposal 3: Ratification of Auditors
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023 (39,864,451 For; 2,087 Against).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Important Facts for Investors to Verify
- Verify the full composition of the Board of Directors following the election of the Class III directors.
- Review the definitive Proxy Statement (Schedule 14A) filed on April 28, 2023, for detailed executive compensation data.
- Confirm the engagement terms with Ernst & Young LLP for the 2023 fiscal year.
- Note that the "Withheld" votes for Richard Heyman, Ph.D. were significantly higher than for the other director nominees.